A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva
- 3 August 2000
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 14 (5) , 338-343
- https://doi.org/10.1002/1099-0801(200008)14:5<338::aid-bmc993>3.0.co;2-6
Abstract
UCN‐01, 7‐hydroxystaurosporine, is an antagonist of protein kinase C, as well as causing cell cycle arrest. We developed and validated an HPLC assay method for the quantitation of UCN‐01. Plasma and saliva standard curves were prepared at concentrations ranging from 0.2 to 20.0 µg/mL and 4.0 to 200.0 ng/mL, respectively. The sample preparation consisted of acetonitrile precipitation. Separation was accomplished on a phenyl column and a C‐18 precolumn insert utilizing a gradient‐profile consisting of ammonium acetate and acetonitrile. UV detection was set at 295 nm for UCN‐01 and 323 nm for umbelliferone, the internal standard. For fluorescence detection, excitation occurred at 290 nm, while emission was at 400 nm. The retention times were around 4 min for umbelliferone and 9.1 for UCN‐01. Inter‐ and intra‐assay errors of accuracy were less than 7.0% and 10.7%, respectively, for the plasma standard curve and less than 7.1% and 6.7%, respectively, for the saliva standard curve. The recoveries of UCN‐01 and umbelliferone from saliva were 81.4 ± 0.9% and 106.3 ± 10.2%, respectively. The recovery of UCN‐01 from plasma was 97.9 ± 7.1% and for umbelliferone was 103.3 ± 2.3%. This method is suitable for quantifying UCN‐01 in patient samples and further characterizing the clinical pharmacology of this compound. Published in 2000 by John Wiley & Sons, Ltd.Keywords
This publication has 6 references indexed in Scilit:
- Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.Cancer Chemotherapy and Pharmacology, 1998
- Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01, in human plasma or urineJournal of Chromatography B: Biomedical Sciences and Applications, 1998
- UCN-01: a Potent Abrogator of G2 Checkpoint Function in Cancer Cells With Disrupted p53JNCI Journal of the National Cancer Institute, 1996
- UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities.The Journal of Antibiotics, 1989
- The Pharmacokinetics of Carbamazepine in Plasma and Saliva of ManActa Pharmacologica et Toxicologica, 1977
- SALIVARY PHENYTOIN CONCENTRATIONS IN EPILEPSY AND IN CHRONIC RENAL FAILUREThe Lancet, 1976